## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.87 indicates fundamental undervaluation. Quality metrics strong (ROE 31%). Caution: momentum weakening (-3.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($62.84)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 1, Bearish: 9)

**1. DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit**
- Source: GlobeNewswire | 20251223T170754 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) alleging that the company made materially false and misleading statements about design changes to its G6 and G7 devices, leading to reliability issues and health risks. Investors who purchased DexCom securities between January 8, 2024, and September 17, 2025, are encouraged to join the lawsuit, with a lead plaintiff deadline of December 26, 2025. The firm seeks to recover damages for investors who suffered losses due to the alleged violations of federal securities laws.

**2. Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc.(DXCM) Shareholders**
- Source: Morningstar | 20251223T140737 | Bearish | Relevance: 100%
- Levi & Korsinsky, LLP has filed a class action securities lawsuit against DexCom, Inc. (NASDAQ: DXCM) on behalf of investors who suffered losses due to alleged securities fraud between January 8, 2024, and September 17, 2025. The lawsuit claims DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and presenting health risks, which the company allegedly concealed. Investors have until December 26, 2025, to request to be appointed lead plaintiff.

**3. Class Action Filed Against DexCom, Inc. (DXCM) Over Securities Violations - Contact Levi & Korsinsky Today**
- Source: FOX40 News | 20251223T010756 | Bearish | Relevance: 100%
- A class action lawsuit has been filed against DexCom, Inc. (DXCM) on behalf of investors who purchased securities between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made false statements and concealed material design changes to its G6 and G7 glucose monitoring products, which were unauthorized by the FDA and rendered the devices less reliable, posing health risks to users. Levi & Korsinsky, LLP is seeking to recover losses for affected shareholders.

**4. DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds DXCM Investors of the December 26th Deadline for Contacting the Firm**
- Source: GlobeNewswire | 20251223T003222 | Bearish | Relevance: 100%
- Bragar Eagel & Squire, P.C. announced a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) for allegedly making false and misleading statements regarding the safety and efficacy of its G6 and G7 devices. Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, are encouraged to contact the firm before the December 26, 2025 deadline to apply for lead plaintiff. The lawsuit claims DexCom made unauthorized design changes that rendered the devices less reliable, posing a health risk to users.

**5. DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm**
- Source: GlobeNewswire | 20251222T150822 | Bearish | Relevance: 100%
- The Schall Law Firm has announced a class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) for alleged securities fraud. The lawsuit claims DexCom made false and misleading statements about unauthorized changes to its G6 and G7 systems, which reportedly made the products less reliable and posed health risks to users. Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, are encouraged to contact the firm before December 26, 2025, to participate and potentially recover losses.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Mizuho | $78 | $75 | +4% |
| 2025-12-11 | Citigroup | $77 | $75 | +3% |
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Mizuho | main | Outperform |
| 2025-12-11 | Citigroup | main | Buy |
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)
- JPMORGAN CHASE & CO: 3.2% (+101.9%)

### Key Risks

1. Long-term trend broken: trading 9.6% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +9%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.87 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (3 raises, avg +9%). Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.2B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.87 |
| Forward P/E | 27.0 |
| Current P/E | 32.4 |
| YoY Growth | 20.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.4% to 1.0% (-3.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.0pp (needs >4.0% for momentum thesis). MRS_5 (-0.9%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.90x), long-term trend not supportive. RSI neutral at 57. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.00% (CS: 66) | Neutral |
| RSI_14 | 57.4 | Neutral |
| MACD Histogram | 0.10 | Bullish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 1.044x | Above |
| vs SMA200 | 0.904x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $66.86
- **Stop Loss:** $62.84 (6.0% risk)
- **Target:** $74.90 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 298
- **Position Value:** $19,924.28
- **Portfolio %:** 19.92%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*